Low Molecular Weight Heparin, Enoxaparin sodium, to Prevent Adverse Maternal and Perinatal Outcomes in Women With Previous Severe Preeclampsia at Less Than 34 Weeks' Gestation. A Prospective Randomized Trial

Trial Profile

Low Molecular Weight Heparin, Enoxaparin sodium, to Prevent Adverse Maternal and Perinatal Outcomes in Women With Previous Severe Preeclampsia at Less Than 34 Weeks' Gestation. A Prospective Randomized Trial

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Dec 2016

At a glance

  • Drugs Aspirin (Primary) ; Enoxaparin sodium (Primary)
  • Indications Embolism and thrombosis; Preeclampsia
  • Focus Therapeutic Use
  • Acronyms HEPEPE; NOH-PE; NOHA
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Nov 2016 Results published in the Obstetrics and Gynecology
    • 06 Oct 2016 Primary endpoint has not been met. (The primary outcome is a composite morbidity that may occur : maternal death, or perinatal death, or preeclampsia, or abruptio placenta, or fetal growth restriction. [ Time Frame: from randomization until one month after the delivery ] [ Designated as safety issue: No ]), according to results published in the Obstetrics and Gynecology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top